NervGen Pharma
$1.62
12
+$0.01+0.62% Wednesday 19:33
Statistik
Harga Tertinggi Hari
1.7
Harga Terendah Hari
1.61
52M Tertinggi
2.99
52M Terendah
1.16
Volum
18,588
Volum Purata
38,195
Kapasiti Pasaran
145.97M
Nisbah P/E
-
Pendapatan Dividen
-
Dividen
-
Akan Datang
Pendapatan
13NovDijangka
EPS yang dijangka
-0.09179134029000001
EPS sebenar
N/A
Orang Lain Juga Mengikuti
Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti NGENF. Ini bukan cadangan pelaburan.
Peserta
Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.
Biogen
BIIB
Kapasiti Pasaran29.83B
Lilly(Eli) &
LLY
Kapasiti Pasaran864.43B
Novavax
NVAX
Kapasiti Pasaran1.98B
Pfizer
PFE
Kapasiti Pasaran164.39B
Merck
MRK
Kapasiti Pasaran300.25B
Abbvie
ABBV
Kapasiti Pasaran346.75B
AMGEN
AMGN
Kapasiti Pasaran179.38B
Astrazeneca
AZN
Kapasiti Pasaran271.67B
Gilead Sciences
GILD
Kapasiti Pasaran98.35B
Mengenai
Pharmaceuticals: Major
Health Technology
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
Show more...
CEO
Pekerja
11
Negara
CA
ISIN
CA64082X2032